EVKEEZA
PeakmAbBLAINJECTIONSOLUTIONPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
EVKEEZA by Regeneron is evinacumab-dgnb is a recombinant human monoclonal antibody that binds to and inhibits angptl3. First approved in 2021.
Drug data last refreshed 6h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVKEEZA (evinacumab) is a monoclonal antibody that inhibits angiopoietin-like 3 (ANGPTL3), a regulator of lipoprotein metabolism. It is indicated for patients with severe hypertriglyceridemia who have inadequate response to other lipid-lowering therapies. The drug works by blocking ANGPTL3 to increase triglyceride clearance and reduce cardiovascular risk.
$7.0MPart D
PeakProduct is at peak lifecycle stage with established market penetration; commercial and medical teams are stable or modestly growing.
Mechanism of Action
Evinacumab-dgnb is a recombinant human monoclonal antibody that binds to and inhibits ANGPTL3. ANGPTL3 is a member of the angiopoietin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism by inhibiting lipoprotein lipase (LPL) and…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia
Started Jun 2020
20 enrolled
Homozygous Familial Hypercholesterolemia
Career Relevance
Working on EVKEEZA at peak lifecycle provides career stability with 542 linked job opportunities across manufacturing, regulatory, and commercial functions. The focus is on operational excellence, procurement optimization, and quality assurance as the product sustains market presence in a specialized indication.
Worked on EVKEEZA at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.